Effect of Bariatric Surgery on Kidney Function (GAS)
Primary hypothesis:
A large reduction in weight is not associated with a change in accurately measured glomerular filtration rate (GFR) (51Chromium ethylenediaminetetraacetic acid plasma clearance (51Cr-EDTA)).
Secondary hypothesis:
A large reduction in weight is associated with a greater change in estimated GFR (The Modification of Diet in Renal Disease (MDRD-formula)) than in accurately measured GFR.
Other formulas for estimated GFR (Cockcroft Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), CKD-EPI with cystatin C) are better correlated with accurately measured GFR.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gentofte, Denmark, 2820
- Peter Rossing
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, older than 18 years of age
- Appointed to gastric by-pass surgery on Hvidovre Hospital, Denmark
Exclusion Criteria:
- Withdrawal of surgical indication
- Severe oedema or ascites
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bariatric surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in accurately measured GFR
Time Frame: Up to 6 months and 18 months after surgery
|
Up to 6 months and 18 months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in estimated GFR (as measured by the MDRD formula, the Cockcroft Gault formula, CKD-EPI formula and CKD-EPI with cystatin C formula).
Time Frame: Up to 6 months and 18 months after surgery
|
Up to 6 months and 18 months after surgery
|
|
Change in 24hour blood pressure
Time Frame: Up to 6 months and 18 months after surgery
|
Up to 6 months and 18 months after surgery
|
|
Change in arterial stiffness (as measured by sphygmocor)
Time Frame: Up to 6 months and 18 months after surgery
|
Up to 6 months and 18 months after surgery
|
|
Change in body composition, as measured by Dual-energy X-ray absorptiometry scan (DXA-scan)
Time Frame: Up to 6 months and 18 months after surgery
|
Up to 6 months and 18 months after surgery
|
|
Change in accurately measured GFR compared with change in estimated GFR
Time Frame: Up to 6 months and 18 months after surgery
|
Up to 6 months and 18 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Peter Rossing, Professor, Steno Diabetes Center Copenhagen
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 3005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obese Subjects Who Will Undergo Gastric By-pass Surgery
-
NCT05647642RecruitingFemale Patients Under the Age of 65 Who Will Undergo Breast Cancer Surgery
-
NCT05565911Active, not recruitingoPAP Should be > 25mmHg in Right Heart Catheterization at Rest | There Should be Patients Who Will Undergo Non-cardiac and Non-obstetric Surgery
-
NCT01712542CompletedPatient Harboring Glioblastoma That Will Undergo Surgery
-
NCT01796145Active, not recruitingConfirmed Diagnosis of Hepatocellular Carcinoma | Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery | Child's A to C Cirrhosis
-
NCT00565799TerminatedPatients Who Consented to Undergo Laparoscopic Gastric Banding Surgery for Weight Loss and Consent to Participate in This studyBMI ≥35 kg/m2 | Confirmed Type 2 Diabetes Treated With Oral Agents and/or Only Diet Therapy | Age 18-64 Years
Clinical Trials on Gastric by-pass surgery
-
NCT02988011UnknownWeight Loss | Bariatric Surgery Candidate | Type2 Diabetes | Insulin Sensitivity | Metabolism and Nutrition Disorder | Metabolism Disorder, Glucose
-
NCT05859022RecruitingObesity | Bariatric Surgery Candidate | Metabolic Disease | Type2diabetes
-
NCT00566943Completed
-
NCT01501201Completed
-
NCT04058730Active, not recruitingType 2 Diabetes Mellitus
-
NCT06600555RecruitingObesity | Diabetes Mellitus, Type 2
-
NCT03983135CompletedBariatric Surgery | Revisional Bariatric Surgery | Obesity Associated Disorder
-
NCT04446546CompletedHemodialysis Access Failure | End Stage Renal Failure on Dialysis
-
NCT00247377Completed
-
NCT01345773CompletedGastric Cancer | Venous Thromboembolism | Postoperative Period